Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells

International Journal of Cancer

Volumn 118, Issue 4, 2006, Pages 832-840

  Sarvilinna, Nanna ^a   Eronen, Heli ^a   Miettinen, Susanna ^a   Vienonen, Annika ^a   Ylikomi, Timo ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Breast cancer; Coregulator; Endocrine resistance; Hormone replacement therapy; Steroid hormone receptor

Indexed keywords

ANTIESTROGEN; ANTIGESTAGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR BETA; HISTONE ACETYLTRANSFERASE PCAF; MEDROXYPROGESTERONE ACETATE; NUCLEAR RECEPTOR COREPRESSOR; PROGESTERONE RECEPTOR; PROTEIN P300; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SILENCING MEDIATOR FOR RETINOID ACID AND THYROID HORMONE RECEPTOR; STEROID RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 1A; STEROID RECEPTOR COACTIVATOR 3; TOREMIFENE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HORMONE RESISTANCE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; RIBONUCLEASE PROTECTION ASSAY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HORMONE REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; PROGESTINS; RECEPTORS, PROGESTERONE; REPRESSOR PROTEINS; TOREMIFENE; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 31544433440     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21431     Document Type: Article

References (47)

1. Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer. Eur J Cancer 1996;32A:576-88.
2. Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer. Oncology 2003;64:289-99.
3. Mouridsen HT, Rose C, Brodie AH, Smith IE. Challenges in the endocrine management of breast cancer. Breast 2003;12(Suppl):S2-19.
4. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
5. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993;26:237-46.
6. Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994;54:349-53.
7. McGuire WL, Chamness GC, Fuqua SA. Abnormal estrogen receptor in clinical breast cancer. J Steroid Biochem Mol Biol 1992;43:243-7.
8. Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE. Estrogen receptor messenger RNA splice variants are not involved in anti-estrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 1997;57:585-9.
9. de Cremoux P, Tran-Perennou C, Brockdorff BL, Boudou E, Brunner N, Magdelenat H, Lykkesfeldt AE. Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with anti-estrogens. Endocr Relat Cancer 2003;10:409-18.
10. Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 1999;59:5421-4.
11. Berns EM, van Staveren IL, Klijn JG, Foekens JA. Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res Treat 1998;48:87-92.
12. Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bieche I. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 2003;9: 1259-66.
13. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 1998;95:2920-5.
14. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
15. Cano A, Hermenegildo C. The endometrial effects of SERMs. Hum Reprod Update 2000;6:244-54.
16. Diez JL. Skeletal effects of selective oestrogen receptor modulators (SERMs). Hum Reprod Update 2000;6:255-8.
17. Goldstein SR. The effect of SERMs on the endometrium. Ann NY Acad Sci 2001;949:237-42.
18. Takimoto GS, Graham JD, Jackson TA, Tung L, Powell RL, Horwitz LD, Horwitz KB. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol 1999;69:45-50.
19. Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem 1989;182:16-9.
20. Vienonen A, Miettinen S, Manninen T, Altucci L, Wilhelm E, Ylikomi T. Regulation of nuclear receptor and cofactor expression in breast cancer cell lines. Eur J Endocrinol 2003;148:469-79.
21. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-8.
22. Thenot S, Charpin M, Bonnet S, Cavailles V. Estrogen receptor cofactors expression in breast and endometrial human cancer cells. Mol Cell Endocrinol 1999;156:85-93.
23. Braunsberg HA, Coldham NG, Wong W. Hormonal therapies for breast cancer: can progestogens stimulate growth? Cancer Lett 1986; 30:213-8.
24. Gibelli N, Zibera C, Sica G, Carbone M, Pedrazzoli P, Robustelli della Cuna G. Morphological and biochemical features of a medroxyprogesterone acetate (MPA)-resistant MCF-7 breast cancer cell line. Anticancer Res 1994;14:37-43.
25. Schoonen WG, Joosten JW, Kloosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. J Steroid Biochem Mol Biol 1995;55:423-37.
26. Ahola TM, Purmonen S, Pennanen P, Zhuang YH, Tuohimaa P, Ylikomi T. Progestin upregulates G-protein-coupled receptor 30 in breast cancer cells. Eur J Biochem 2002;269:2485-90.
27. Kangas L, Nieminen AL, Blanco G, Gronroos M, Kallio S, Karjalainen A, Perila M, Sodervall M, Toivola R. A new triphenylethylene compound. Fc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 1986;17:109-13.
28. Grenman R, Laine KM, Klemi PJ, Grenman S, Hayashida DJ, Joensuu H. Effects of the anti-estrogen toremifene on growth of the human mammary carcinoma cell line MCF-7. J Cancer Res Clin Oncol 1991;117:223-6.
29. Lykkesfeldt AE, Briand P. Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. Br J Cancer 1986;53:29-35.
30. Lykkesfeldt AE, Sorensen EK. Effect of estrogen and anti-estrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol 1992;31:131-8.
31. Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line. MCF-7/TAMR-1. Cancer Res 1994;54:1587-95.
32. Herman ME, Katzenellenbogen BS. Response-specific anti-estrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. J Steroid Biochem Mol Biol 1996;59:121-34.
33. Badia E, Duchesne MJ, Semlali A, Fuentes M, Giamarchi C, Richard-Foy H, Nicolas JC, Pons M. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res 2000;60:4130-8.
34. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term anti-estrogen administration. Cancer Res 1988;48:5183-7.
35. Fujita T, Kobayashi Y, Wada O, Tateishi Y, Kitada L, Yamamoto Y, Takashima H, Murayama A, Yano T, Baba T, Kato S, Kawabe Y, et al. Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells. J Biol Chem 2003;278: 26704-14.
36. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed anti-estrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997;11:657-66.
37. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003;278:30458-68.
38. Pink JJ, Jiang SY, Fritsch M, Jordan VC. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res 1995;55:2583-90.
39. Herman ME, Katzenellenbogen BS. Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 1994;54:5867-74.
40. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25.
41. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002;81:333-41.
42. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S, Santen RJ. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998;139:4164-74.
43. Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kumar R, Santen RJ. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000;141:396-405.
44. Song RX, Santen RJ, Kumar R, Adam L, Jeng MH, Masamura S, Yue W. Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Mol Cell Endocrinol 2002;193:29-42.
45. Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME, Clarke R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 1993;53: 283-90.
46. Darbre PD, Daly RJ. Transition of human breast cancer cells from an oestrogen responsive to unresponsive state. J Steroid Biochem Mol Biol 1990;37:753-63.
47. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomized comparison: trial stopped. Lancet 2004;363:453-5.